Selecta Biosciences
480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States
Tel: 617-923-1400
Fax: 617-924-3454
Website: http://www.selectabio.com/
Email: info@selectabio.com
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
Exchange: NASDAQ
156 articles with Selecta Biosciences
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights
4/30/2020
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that it plans to host a conference call on Thursday, May 07, 2020, at 8:30 a.m. ET to discuss its first quarter financial results and recent operational highlights. Individuals may participate in the live call via telephone by dialin
-
Selecta Biosciences Appoints Dr. Goran Ando to its Board of DirectorsGlobal pharmaceutical and biotech industry veteran brings significant clinical expertise and business acumen to help advance the Company’s immune tolerance platform
4/28/2020
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Dr. Goran Ando to its Board of Directors, replacing Amir Nashat, effective April 24, 2020. Amir will continue to serve in an advisory capacity to Selecta. “The addition of Dr. Ando to our Board means that Selecta
-
Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
4/7/2020
Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14 at 10:40 a.m. Eastern Time.
-
Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results
3/12/2020
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today reported financial results for the fourth quarter and year ended December 31, 2019.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
3/5/2020
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on Thursday, March 12, 2020, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2019, and recent operational highlights.
-
Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/18/2020
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference in New York on Tuesday, February 25 at 11:00 a.m. Eastern Time.
-
Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212
12/19/2019
Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, announced the completion of patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial.
-
Selecta Biosciences Announces $70 Million Private Placement
12/19/2019
Selecta Biosciences, Inc. announced that it has entered into definitive agreements to sell securities in a private placement with a group of institutional investors and certain members of the Company’s Board of Directors.
-
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
12/19/2019
AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease
-
Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors
11/21/2019
Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s ImmTOR™ platform
-
Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference
11/12/2019
Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19 at 1:50 p.m. Eastern Time.
-
Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
11/11/2019
Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies
-
Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/8/2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.
-
Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call
11/1/2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to issue its third quarter 2019 financial results on Friday November 8, 2019.
-
Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
10/24/2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that data from the company’s completed Phase 2 dose ranging study of SEL-21 (NCT02959918) for the treatment of chronic refractory gout will be presented at the upcoming 2019 American College of Rheumatology (ACR) Annual Meeting being held from November 8-13, 2019 in Atlanta, GA.
-
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
10/23/2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today presented new preclinical data from its gene therapy program at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress from October 22-25, 2019 in Barcelona, Spain.
-
BioSpace Movers and Shakers, July 19
7/19/2019
Pharma and biotech companies from across the globe expand their leadership teams and boards. -
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
7/15/2019
Alison is an extremely accomplished senior leader with over 20 years of combined drug development, strategic management and practical clinical experience in academia and industry, successfully leading multiple clinical programs to approval
-
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
-
Bioscience Companies Deliver Life-Changing Products to Patients Faster with Help from NetSuite
8/13/2018
To accelerate the commercialization of life-changing products, bioscience companies are selecting Oracle NetSuite.